Domperidone for Lactation: What Health Care Providers Need to Know

Area of Science:

• Pharmacology
• Lactation Medicine
• Public Health

Background:

• Breastfeeding offers significant maternal and infant health benefits.
• Insufficient milk production is a primary cause of early breastfeeding cessation.
• Domperidone is explored for lactation enhancement despite lacking regulatory approval for this indication.

Purpose of the Study:

• To inform healthcare providers about domperidone's regulatory status and evidence for lactation.
• To highlight the safety concerns and limited efficacy data for domperidone in enhancing milk production.
• To emphasize the U.S. Food and Drug Administration's (FDA) warnings against its use.

Main Methods:

• Review of regulatory status and scientific literature on domperidone for lactation.
• Analysis of evidence regarding domperidone's efficacy in increasing milk supply.
• Assessment of domperidone's safety profile, particularly cardiac risks.

Main Results:

• Domperidone is not approved for human use in the United States and lacks approval for lactation enhancement globally.
• The FDA has issued import alerts and safety warnings concerning domperidone due to illegal importation and use.
• Limited high-quality evidence supports domperidone's effectiveness for lactation, contrasted with significant data on cardiac risks (QT prolongation, arrhythmias, sudden death).

Conclusions:

• The known cardiac risks of domperidone do not appear to be offset by limited evidence of efficacy for lactation enhancement.
• Healthcare providers are cautioned against using domperidone for lactation due to safety concerns and lack of approval.
• Further research and drug development are necessary to address the unmet medical need for effective and safe lactation support.